Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 6

Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease

Authors Sims MW, Panettieri, Jr. RA

Published 16 September 2011 Volume 2011:6 Pages 457—466

DOI https://doi.org/10.2147/COPD.S15524

Review by Single-blind

Peer reviewer comments 3

Michael W Sims, Reynold A Panettieri, Jr.
Pulmonary, Allergy, and Critical Care Division, Airways Biology Initiative, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

Abstract: Bronchodilators provide the mainstay of pharmacologic therapy for chronic obstructive pulmonary disease (COPD), and anticholinergic bronchodilators, in particular, appear to be the most effective. There are currently two anticholinergic agents available in the US for the treatment of COPD (ipratropium bromide and tiotropium bromide), but several others are in various stages of development. Aclidinium bromide, a novel, long-acting, anticholinergic bronchodilator, is currently in Phase III trials for the management of COPD. Available evidence suggests that aclidinium is a safe and well tolerated drug with a relatively rapid onset and a sufficient duration of action to provide once-daily dosing. This article will provide a pharmacologic profile of aclidinium bromide and review the preclinical and clinical studies evaluating its safety and efficacy in the treatment of COPD.

Keywords: aclidinium bromide, bronchodilators, pulmonary disease, chronic obstructive, muscarinic antagonists, pharmacokinetics, pharmacology

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Impact of night-time symptoms in COPD: a real-world study in five European countries

Price D, Small M, Milligan G, Higgins V, Garcia Gil E, Estruch J

International Journal of Chronic Obstructive Pulmonary Disease 2013, 8:595-603

Published Date: 27 November 2013

Safety of indacaterol in the treatment of patients with COPD

Donohue JF, Singh D, Kornmann O, Lawrence D, Lassen C, Kramer B

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:477-492

Published Date: 22 September 2011

Spirometric testing on World COPD Day

Tanja Grzetic-Romcevic, Boris Devcic, Silvana Sonc,

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:141-146

Published Date: 10 February 2011

Early detection of COPD in general practice

Charlotte Suppli Ulrik, Anders Løkke, Ronald Dahl, et al

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:123-127

Published Date: 28 January 2011

Prevalence and risk factors for unrecognized obstructive lung disease among urban drug users

M Bradley Drummond, Gregory D Kirk, Jacquie Astemborski, et al

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:89-95

Published Date: 19 January 2011

Optimizing management of chronic obstructive pulmonary disease in the upcoming decade

Richard Russell, Antonio Anzueto, Idelle Weisman

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:47-61

Published Date: 10 January 2011

Improving adherence with inhaler therapy in COPD

Suzanne C Lareau, Barbara P Yawn

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:401-406

Published Date: 24 November 2010